Sfoglia per Autore
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies
2019 de Giglio A.; Nuvola G.; Gustavo Dall'Olio F.
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect
2019 Nuvola G.; Dall'Olio F.G.; Melotti B.; Sperandi F.; Ardizzoni A.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio A.; Nuvola G.; Baldini C.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D.
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory?
2021 Marchetti A.; Rosellini M.; Mollica V.; Rizzo A.; Tassinari E.; Nuvola G.; Cimadamore A.; Santoni M.; Fiorentino M.; Montironi R.; Massari F.
Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma
2021 DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P, De; Leo A, De; A, Astolfi; MA, Pantaleo
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases
2021 Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi Raffaele; Franceschi Enrico; Brandes Alba Ariela
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution
2021 Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
2021 De Giglio A.; Di Federico A.; Nuvola G.; Deiana C.; Gelsomino F.
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
2021 Di Federico A.; Nuvola G.; Deiana C.; Donati G.; De Giglio A.
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt
2021 Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi R.; Massari F.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022 Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M.
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?
2022 Nuvola G.; Rizzo A.; Mollica V.; Massari F.
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D.
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile